Halozyme Therapeutics, Inc. · NASDAQ:HALO
Halozyme Therapeutics — Q3 2022 Earnings Presentation
17 slides from Halozyme Therapeutics's earnings presentation, Nov 8, 2022
Slide 1: Third Quarter 2022 Financial and Operating Results
Third Quarter 2022 Financial and Operating Results Nasdaq: HALO November 8, 2022 Halozyme Confidential and Proprietary
Slide 2: Forward-Looking Statements
Forward-Looking Statements In addition to historical information, the statements set forth in this presentation include forward-looking statements including, without limitation, statements concerning the Company’s expected future financial performance (including the Company's financial outlook for 2
Slide 3: Halozyme 3Q 2022 Financial and Operating Highlights
Halozyme 3Q 2022 Financial and Operating Highlights 3Q 2022 revenue increased 80% YOY to $209 million with GAAP diluted EPS of $0.44 and non-GAAP diluted EPS of $0.74 Record 3Q 2022 royalty revenue increased 70% YOY to $99.6 million Expanded leadership in drug delivery technology with a specialty bu
Slide 4: Strong Royalty Growth Driven By ENHANZE and Device Royalties
Halozyme Strong Royalty Growth Driven By ENHANZE ® and Device Royalties 70% year-over-year growth Project >70% year-over-year growth in 17% sequential growth in 3Q 2022 2022 Quarterly Royalty Revenue ($M) Annual Royalty Revenue ($M) $350-$360 $99.6 $85.3 $69.6 $203.9 $58.6 $62.6 $45.8 $36.9 $32.0 $8
Slide 5: Total DARZALEX, DARZALEX FASPRO and DARZALEX SC Growth
Total DARZALEX, DARZALEX FASPRO® and DARZALEX SC Wave 1 2 3 4 Growth DARZALEX FASPRO® Share of Total US Total Daratumumab Sales DARZALEX® Sales1 IV+SC ($B) 2 $13.0 $12.0 $10.9 83% 85% $9.5 76% 80% 72% $8.0 66% $6.0 $4.2 2020 2021 2022E 2023E 2024E 2025E 2026E Q2 2021 Q3 2021 Q4 2021 Q1 2022 Q2 2022
Slide 6: ENHANZE: Durable Revenue Potential and Strong Future Growth Opportunities
ENHANZE®: Durable Revenue Potential and Strong Future Growth Opportunities Wave 1 & 2 Wave 3 Wave 4 Wave 5 5 Globally Approved 4 Product Candidates 11 Product Candidates New Nominations Products in in in Phase 3e 3 from Current and 10 in/completed Phase 1 Atezolizumab SC New Partners 1 in Phase 3 Ef
Slide 7: Wave 3 Pipeline Supports Potential Launches in 2023-2025
Wave Wave 3 Pipeline Supports Potential Launches in 2023-2025 1 2 3 4 Product Disease Areas Milestone Completed SC with ENHANZE® BLA Myasthenia Gravis submission in September 2022 Efgartigimod IV APPROVED Other Indications Additional SC with ENHANZE® data readouts projected: 2023 Atezolizumab IV APP
Slide 8: ENHANZE Partner Product Development Pipeline
ENHANZE® Partner Product Development Pipeline Wave 4 Products Current Program/Product Indications Phase 1 Phase 2 Phase 3 Filed Wave 4 Amivantamab (Janssen) Solid malignancies Nivolumab+Relatlimab (BMS) Solid tumors ARGX-117 (argenx) Multifocal motor neuropathy CAP256V2LS (CAPRISA) HIV Teprotumumab-
Slide 9: Technology Platforms with Broad Applicability and Innovation Potential
Technology Platforms with Broad Applicability and Innovation Potential ENHANZE® Technology Auto-Injector Technology Commercially validated ENHANZE® Leading auto-injector platform and platform technology with world- domain expertise class partners Flexible delivery force, injection speed and needle l
Slide 10: Halozyme Strategic and Capital Allocation Priorities
Halozyme Strategic and Capital Allocation Priorities Invest to Maximize Continue to Return Identify Revenue Growth Capital Opportunities for and Durability to Shareholders External Growth Second Plan: December 2021 • Focus on integration • $750M 3-year share buyback announced • ENHANZE® • Continue t
Slide 11: 3Q 2022 Financial Highlights
3Q 2022 Financial Highlights $ U.S. in Millions, except EPS (unaudited) 3Q 2022 3Q 2021 % Change Royalties $99.6 $58.6 70.0% Product sales, net $61.4 $25.0 145.2% Collaboration Revenues $48.0 $32.2 49.0% Total Revenues $209.0 $115.8 80.4% Cost of sales $47.3 $18.6 154.6% Amortization of intangibles
Slide 12: 2022 Financial Guidance Highlights
2022 Financial Guidance Highlights 2021 2022 • ~48-55% YoY growth • Includes Antares beginning May 24, 2022 which is expected to Total Revenue $443.3M $655M-$685M contribute $115M - $125M • Product Sales expected to increase from 2021 due to contribution of sales from Antares • >70% YoY growth Royal
Slide 13: Thank You!
Thank You! Halozyme Confidential and Proprietary
Slide 14: 3Q 2022 Financial Results Appendix
3Q 2022 Financial Results Appendix Halozyme Confidential and Proprietary
Slide 15: GAAP to Non-GAAP Reconciliation: Net Income and Diluted EPS
GAAP to Non-GAAP Reconciliation: Net Income and Diluted EPS $ U.S. in thousands, except per share amounts (unaudited) Dollar amounts, as presented, are rounded. Consequently, totals may not add up. (1) Amount represents incremental costs including legal fees, accounting fees and advisory fees incurr
Slide 16: GAAP to Non-GAAP Reconciliation: Net Income and Diluted EPS 2022 Guidance
GAAP to Non-GAAP Reconciliation: Net Income and Diluted EPS 2022 Guidance $ U.S. in Millions, except EPS (unaudited) Dollar amounts, as presented, are rounded. Consequently, totals may not add up. Halozyme Confidential and Proprietary 16
Slide 17: GAAP to Non-GAAP Reconciliation: Operating Income 2022 Guidance
GAAP to Non-GAAP Reconciliation: Operating Income 2022 Guidance $ U.S. in Millions, (unaudited) Dollar amounts, as presented, are rounded. Consequently, totals may not add up (1) Adjusted operating Income is adjusted for acquisition related costs Halozyme Confidential and Proprietary 17
Halozyme Therapeutics — Q3 2022 Earnings Presentation on 6ix